High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). (June 2017)

Record Type:: Journal Article
Title:: High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL). (June 2017)
Main Title:: High response rates and safe toxic profile of brentuximab vedotin/bendamustine combination in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma (HL)
Authors:: Wannesson, B.
Remaggi, G.
Intile, D.
Ferrari, L.
Cruset, S.
Fernández, I.
Miodosky, M.
Cugliari, M.S.
Bordone, J.
Pavlovsky, M.A.
Abstract:
Is Part Of:: Hematological oncology. Volume 35(2017)Supplement 2
Journal:: Hematological oncology
Issue:: Volume 35(2017)Supplement 2
Issue Display:: Volume 35, Issue 2 (2017)
Year:: 2017
Volume:: 35
Issue:: 2
Issue Sort Value:: 2017-0035-0002-0000
Page Start:: 320
Page End:: 320
Publication Date:: 2017-06
Subjects:: Hematological oncology -- Periodicals
Hematology
Medical Oncology
616.99418005
Journal URLs:: http://onlinelibrary.wiley.com/ ↗
DOI:: 10.1002/hon.2439_61 ↗
Languages:: English
ISSNs:: 0278-0232
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 4291.550000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 1268.xml